Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · IEX Real-Time Price · USD
8.23
-0.86 (-9.46%)
May 1, 2024, 4:00 PM EDT - Market closed
Acrivon Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for ACRV stock have an average target of 22.63, with a low estimate of 14 and a high estimate of 30. The average target predicts an increase of 174.97% from the current stock price of 8.23.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ACRV stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 4 |
| Buy | 4 | 4 | 4 | 4 | 3 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 6 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BMO Capital | BMO Capital | Buy Maintains $18 → $25 | Buy | Maintains | $18 → $25 | +203.77% | Apr 26, 2024 |
| JMP Securities | JMP Securities | Buy Maintains $14 → $17 | Buy | Maintains | $14 → $17 | +106.56% | Apr 25, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $26 → $30 | Buy | Maintains | $26 → $30 | +264.52% | Apr 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +143.01% | Apr 25, 2024 |
| Ladenburg Thalmann | Ladenburg Thalmann | Strong Buy Maintains $18 → $14 | Strong Buy | Maintains | $18 → $14 | +70.11% | Apr 5, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
1.03M
EPS This Year
-3.57
from -2.74
EPS Next Year
-3.38
from -3.57
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | n/a | 5.3M | 55.0M | 220.6M | 301.5M |
| Avg | n/a | 1.0M | 18.1M | 101.7M | 178.7M |
| Low | n/a | n/a | n/a | 9.8M | 101.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | 5,231.4% | 1,119.2% | 196.4% |
| Avg | - | - | 1,652.8% | 462.2% | 75.7% |
| Low | - | - | - | -45.8% | -0.4% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -3.15 | -2.49 | -2.10 | -2.30 | -1.72 |
| Avg | -3.57 | -3.38 | -2.99 | -3.10 | -3.03 |
| Low | -4.33 | -4.30 | -4.26 | -4.41 | -4.21 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.